<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To study beta2-GP-I-dependent binding of <z:chebi fb="0" ids="16247">phospholipid</z:chebi> antibodies (PAb) to <z:chebi fb="1" ids="16247">phospholipids</z:chebi> and this process participation in pathogenesis of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: IgG-fractions and sera from 20 patients with APS </plain></SENT>
<SENT sid="2" pm="."><plain>Cofactor activity of beta2-GP-I isolated from serum of healthy donors was examined with modified immunoassay </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Contrary to donor IgG, binding of IgG fractions isolated from sera of APS patients with <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> grows dose-dependently in the presence of beta2-GP-I </plain></SENT>
<SENT sid="4" pm="."><plain>Cofactor activity of beta2-GP-I is confirmed in the study of sera of APS patients </plain></SENT>
<SENT sid="5" pm="."><plain>Sera containing beta2-GP-I-dependent antibodies to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> (aCL), unlike aCL-negative sera, react with solid-phase immobilized beta2-GP-I </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: It is confirmed that beta2-GP-I participates in interaction of PAb with <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Pathogenetic implication of beta2-GP-I-dependent PAb for <z:hpo ids='HP_0003674'>onset</z:hpo> of APS is discussed </plain></SENT>
</text></document>